Key result
Dual-specificity tyrosine-regulated kinases (DYRKs) regulate cardiomyocyte proliferation, apoptosis, hypertrophy, and fibrosis, serving as promising preclinical targets for cardiovascular disease.
Why the study?
Current research on the dual-specificity tyrosine-regulated kinase (DYRK) family in cardiovascular diseases lacks systematic integration of isoform-specific functions, spatiotemporal effects, and bidirectional regulatory roles.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
This review synthesizes the isoform-specific molecular mechanisms of the DYRK kinase family in cardiovascular pathology and outlines a translational framework for developing isoform-selective, cardiac-targeted therapies.
Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, characterized by myocardial injury, pathological structural remodeling, and progressive deterioration of cardiac function. Clinical manifestations include post-infarct functional impairment, pathological cardiac hypertrophy, interstitial fibrosis, malignant arrhythmias, and end-stage heart failure. Although the dual-specificity tyrosine-regulated kinase (DYRK) family has been extensively investigated in cancer and neurodegenerative disorders, emerging evidence highlights DYRKs as critical upstream regulators in a wide spectrum of cardiovascular pathological processes. However, current research is largely confined to individual isoforms or isolated signaling pathways, lacking systematic integration of isoform-specific functions, dose- and spatiotemporal-dependent effects, as well as bidirectional regulatory roles in chronic cardiac remodeling. This review systematically summarizes the molecular mechanisms of the DYRK family across major cardiovascular disease models, with particular emphasis on the functional specificity of distinct DYRK isoforms and their translational potential as therapeutic targets. We further provide an integrated theoretical framework to facilitate the development of isoform-selective, context-dependent precision therapies for cardiovascular diseases.
Jiang et al. (2026) conducted a review in Cardiovascular diseases (including myocardial infarction, cardiac hypertrophy, myocardial fibrosis, heart failure, myocardial ischemia-reperfusion injury, Down syndrome-associated congenital heart disease, and metabolic syndrome). Pharmacological or genetic modulation of dual-specificity tyrosine-regulated kinases (DYRKs), including small-molecule inhibitors (harmine, leucettine-21, leucettine-92, EGCG, AZ191, C17) and RNA interference (shRNA, siRNA) was evaluated. Dual-specificity tyrosine-regulated kinases (DYRKs) regulate cardiomyocyte proliferation, apoptosis, hypertrophy, and fibrosis, serving as promising preclinical targets for cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: